The improvement in this patient's neutrophilia and CSF3R mutation VAF with RCD chemotherapy are promising signs, and further research is required to understand whether this regimen could play a role as a future treatment in patients with both CNL and plasma cell dyscrasia. This evidence concerns the gene CSF3R and chronic neutrophilic leukemia.